Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Biologic DMARDs appear as effective in elderly-onset RA as in young-onset RA

Key clinical point: Elderly-onset RA patients are less likely than are young-onset patient to receive bDMARDs but have similar benefit at 48 weeks.

Major finding: Significantly fewer elderly-onset RA patients received bDMARDs (18.3% vs. 28%), but CDAI score at 48 weeks was similar in the groups (odds ratio, 1.01).

Study details: An analysis of registry data for 989 patients.

Disclosures: The investigators reported having no relevant disclosures.

Citation:

Jinno S et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract 1345.